

ost is in DialUnits
? b 410
05jul10 08:11:26 User208760 Session D3198.1
\$0.58 0.154 DialUnits File1
\$0.02 TELNET
\$0.60 Estimated cost this search
\$0.60 Estimated total session cost 0.154 DialUnits

File 410:The Chronolog 1991-2010/ Mar
(c) 2010 Dialog. All rights reserved.

Set Items Description
--- -----
? set hi ;set hi
HIGHLIGHT set on as ''
HIGHLIGHT set on as ''
? begin 5,73,155,399
05jul10 08:11:35 User208760 Session D3198.2
\$0.00 0.115 DialUnits File410
\$0.00 Estimated cost File410
\$0.05 TELNET
\$0.05 Estimated cost this search
\$0.65 Estimated total session cost 0.269 DialUnits

SYSTEM:OS - DIALOG OneSearch
File 5:Biosis Previews(R) 1926-2010/Jul W1
(c) 2010 The Thomson Corporation
File 73:EMBASE 1974-2010/Jul 05
(c) 2010 Elsevier B.V.
*File 73: The archive of Medline derived records was added to Embase.
File 155:MEDLINE(R) 1950-2010/Jul 02
(c) format only 2010 Dialog
*File 155: Medline has been reloaded. Please see HELP NEWS154
for information.
File 399:CA SEARCH(R) 1967-2010/UD=15302
(c) 2010 American Chemical Society
*File 399: Use is subject to the terms of your user/customer agreement.
IPCR/8 classification codes now searchable as IC=. See HELP NEWSIPCR.

Set Items Description
--- -----
? e au=deisseroth albert ?

Ref Items Index-term
E1 2 AU=DEISSEROTH AB
E2 61 AU=DEISSEROTH ALBERT
E3 0 *AU=DEISSEROTH ALBERT ?
E4 103 AU=DEISSEROTH ALBERT B
E5 38 AU=DEISSEROTH K
E6 61 AU=DEISSEROTH K.
E7 101 AU=DEISSEROTH KARL
E8 1 AU=DEISSEROTH WENDY
E9 13 AU=DEISSEROTH, A.
E10 6 AU=DEISSEROTH, A. B.
E11 1 AU=DEISSEROTH, AL
E12 66 AU=DEISSEROTH, ALBERT

Enter P or PAGE for more
? s e1-e4
2 AU=DEISSEROTH AB

```

61 AU=DEISSEROOTH ALBERT
0 AU=DEISSEROOTH ALBERT ?
103 AU=DEISSEROOTH ALBERT B
S1 166 E1-E4
? e au=zhang lixin ?

Ref    Items  Index-term
E1      3    AU=ZHANG LIXIAO
E2      269   AU=ZHANG LIXIN
E3      0    *AU=ZHANG LIXIN ?
E4      2    AU=ZHANG LIXIN LILLY
E5      1    AU=ZHANG LIXIN ZHU LIPING
E6      10   AU=ZHANG LIXING
E7      1    AU=ZHANG LIXING KAN GUANQING
E8      4    AU=ZHANG LIXIONG
E9      1    AU=ZHANG LIXUAN
E10     22   AU=ZHANG LIXUE
E11     12   AU=ZHANG LIXUN
E12     4    AU=ZHANG LIYA

Enter P or PAGE for more

? s e2
S2      269   AU='ZHANG LIXIN'
? s (S1 or s2) and (adenoviral or adenovirus)(20n)(vector?) and (Cd40L or cd154 or
cd40(w)ligand)
166   S1
269   S2
42047  ADENOVIRAL
136081  ADENOVIRUS
694836  VECTOR?
48856  (ADENOVIRAL OR ADENOVIRUS) (20N)VECTOR?
10347  CD40L
4611   CD154
42860  CD40
661511  LIGAND
19956  CD40(W)LIGAND
S3      12   (S1 OR S2) AND (ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?)
          AND (CD40L OR CD154 OR CD40(W)LIGAND)

? rd s3
S4      10  RD S3  (unique items)
? t s4/3/all

4/3/1  (Item 1 from file: 5)
DIALOG(R)File  5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0021275602  BIOSIS NO.: 200900617039
Use of CD40L immunoconjugates to overcome the defective immune
response to vaccines for infections and cancer in the aged
AUTHOR: Tang Yu Cheng; Thoman Marilyn; Linton Phyllis-Jean; Deisseroth
Albert (Reprint)
AUTHOR ADDRESS: US FDA, Off Oncol Drug Prod, 10903 New Hampshire Ave, Bldg
22, Room 6378, Silver Spring, MD 20993 USA**USA
AUTHOR E-MAIL ADDRESS: albert.deisseroth@yahoo.com
JOURNAL: Cancer Immunology Immunotherapy 58 (12): p1949-1957 DEC 2009 2009
ITEM IDENTIFIER: doi:10.1007/s00262-009-0718-3
ISSN: 0340-7004
DOCUMENT TYPE: Article; Literature Review
RECORD TYPE: Abstract
LANGUAGE: English

```

4/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0020916731 BIOSIS NO.: 200900257065
TAA/ecdCD40L VFP Vaccination Induces Robust Adaptive Immune Response Even
in Individuals with Post Transplantation Lymphopenia
AUTHOR: Tang Yucheng (Reprint); Park Yeon Hee; Maynard Jonathan; Li
Pingchuan; Akbulut Hakan; Petersen Line; Deisseroth Albert B
AUTHOR ADDRESS: Sidney Kimmel Canc Ctr, San Diego, CA USA**USA
JOURNAL: Blood 112 (11): p141-142 NOV 16 2008 2008
CONFERENCE/MEETING: 50th Annual Meeting of the American-
Society-of-Hematology San Francisco, CA, USA December 06 -09, 2008;
20081206
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0019615830 BIOSIS NO.: 200700275571
Subcutaneous injection of the Ad-sig-TAA/ecdCD40L adenoviral
vector encoding a CD40ligand/tumor associated antigen secretory
protein generates T cell dependent cellular immunity against tumor cell
lines for up to one year.
AUTHOR: Tang Yucheng (Reprint); Zhang Lixin; Yuan Jing; Akbulut Hakan
; Maynard Jonathan; Linton Phyllis-Jean; Deisseroth Albert B
AUTHOR ADDRESS: Sidney Kimmel Canc Ctr, San Diego, CA USA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting 45 (Suppl. S): p282-283 MAR 2004 2004
CONFERENCE/MEETING: 95th Annual Meeting of the
American-Association-for-Cancer-Research Orlando, FL, USA March 27 -31,
2004; 20040327
SPONSOR: Amer Assoc Canc Res
ISSN: 0197-016X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

18788546 BIOSIS NO.: 200600133941
Vector prime-protein boost vaccine induces immune response against
"self-antigens" associated with epithelial neoplasms and tumor vascular
endothelial cells.
AUTHOR: Tang Yucheng (Reprint); Maynard Jonathan; Akbulut Hakan; Linton
Phyllis-Jean; Deisseroth Albert B
AUTHOR ADDRESS: Sidney Kimmel Canc Ctr, Gene Therapy Program, San Diego, CA
USA**USA
JOURNAL: Blood 106 (11, Part 2): p471B-472B NOV 16 2005 2005
CONFERENCE/MEETING: 47th Annual Meeting of the
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;

20051210
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

18415151 BIOSIS NO.: 200510109651
Adenoviral vectors for targeting of cancer cells
AUTHOR: Deisseroth Albert (Reprint); Tang Yucheng; Liu Yanzheng;
Akbulut Hakan; Maynard Jonathan; Zhang Lixin; Linton Phyllis- Jean
AUTHOR ADDRESS: Sidney Kimmel Canc Ctr, San Diego, CA USA**USA
JOURNAL: Cancer Gene Therapy 11 (12): p847 DEC 04 2004
CONFERENCE/MEETING: Meeting of the
International-Society-for-Cancer-Gene-Therapy February 20 -22, 2004;
20040220
SPONSOR: Int Soc Cancer Gene Therapy
ISSN: 0929-1903
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17781412 BIOSIS NO.: 200400148073
An adenoviral vector cancer vaccine that delivers a tumor
associated antigen/CD40-ligand fusion protein to dendritic
cells in vivo and thereby breaks tolerance to tumor associated self
antigens.
AUTHOR: Tang Yucheng (Reprint); Zhang Lixin (Reprint); Akbulut Hakan
(Reprint); Linton Phyllis-Jean (Reprint); Deisseroth Albert B
(Reprint)
AUTHOR ADDRESS: Genetic Therapy Program, Sidney Kimmel Cancer Center, San
Diego, CA, USA**USA
JOURNAL: Blood 102 (11): p745a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of
Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

4/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17721687 BIOSIS NO.: 200400090456
An adenoviral vector cancer vaccine that delivers a
tumor-associated antigen/CD40-ligand fusion protein to
dendritic cells.

AUTHOR: Zhang Lixin; Tang Yucheng; Akbulut Hakan; Zelterman Daniel;
Linton Phyllis-Jean; Deisseroth Albert B (Reprint)
AUTHOR ADDRESS: Sidney Kimmel Cancer Center, San Diego, CA, 92121, USA**USA
AUTHOR E-MAIL ADDRESS: adeisseroth@skcc.org
JOURNAL: Proceedings of the National Academy of Sciences of the United
States of America 100 (25): p15101-15106 December 9, 2003 2003
MEDIUM: print
ISSN: 0027-8424 _(ISSN print)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

4/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17530335 BIOSIS NO.: 200300487992
Injection of adenoviral vector encoding a secretable form of
the E7/CD40 ligand generates immunoresistance to E7 positive
cell lines for over 1 year.
AUTHOR: Tang Yucheng (Reprint); Zhang Lixin (Reprint); Maynard
Jonathan (Reprint); Deisseroth Albert (Reprint)
AUTHOR ADDRESS: Sidney Kimmel Cancer Center, San Diego, CA, USA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual
Meeting 44 p589 July 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 94th Annual Meeting of the American Association for
Cancer Research Washington, DC, USA July 11-14, 2003; 20030711
ISSN: 0197-016X
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Citation
LANGUAGE: English

4/3/9 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2010 Dialog. All rts. reserv.

17402648 PMID: 16928818
Antitumor immune response induced by i.t. injection of vector-activated
dendritic cells and chemotherapy suppresses metastatic breast cancer.
Akbulut Hakan; Tang Yucheng; Akbulut K Gonca; Maynard Jonathan; Zhang
Lixin; Deisseroth Albert
Sidney Kimmel Cancer Center, 10835 Road to the Cure, San Diego, CA 92121,
USA.
Molecular cancer therapeutics (United States) Aug 2006, 5 (8)
p1975-85, ISSN 1535-7163--Print 1535-7163--Linking Journal Code:
101132535
Publishing Model Print
Document type: Comparative Study; Journal Article; Research Support,
Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed

4/3/10 (Item 2 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2010 Dialog. All rts. reserv.

16204250 PMID: 15238426
Multistep process through which adenoviral vector vaccine
overcomes anergy to tumor-associated antigens.
Tang Yucheng; Zhang Lixin; Yuan Jing; Akbulut Hakan; Maynard
Jonathan; Linton Phyllis-Jean; Deisseroth Albert
Sidney Kimmel Cancer Center, 10835 Altman Row, San Diego, CA 92121, USA.
Blood (United States) Nov 1 2004, 104 (9) p2704-13, ISSN 0006-4971
--Print 0006-4971--Linking Journal Code: 7603509
Publishing Model Print-Electronic
Document type: Journal Article; Research Support, Non-U.S. Gov't;
Research Support, U.S. Gov't, Non-P.H.S.
Languages: ENGLISH
Main Citation Owner: NLM
Record type: MEDLINE; Completed
? s (adenoviral or adenovirus)(20n)(vector?)(20n)(Cd40L or cd154 or cd40(w)ligand)
42047 ADENOVIRAL
136081 ADENOVIRUS
694836 VECTOR?
10347 CD40L
4611 CD154
42860 CD40
661511 LIGAND
19956 CD40(W)LIGAND
S5 379 (ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?) (20N) (CD40L OR
CD154 OR CD40(W)LIGAND)
? s (adenoviral or adenovirus)(20n)(vector?)(20n)(Cd40L or cd154 or
cd40(w)ligand)(20n)(secret?)
42047 ADENOVIRAL
136081 ADENOVIRUS
694836 VECTOR?
10347 CD40L
4611 CD154
42860 CD40
661511 LIGAND
19956 CD40(W)LIGAND
1567357 SECRET?
S6 29 (ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?) (20N) (CD40L OR
CD154 OR CD40(W)LIGAND) (20N) (SECRET?)
? rd s6
S7 15 RD S6 (unique items)
? t s7/3/all
7/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.
0021031254 BIOSIS NO.: 200900372691
Generation of Human Dendritic Cells That Simultaneously Secrete IL-12 and
Have Migratory Capacity by Adenoviral Gene Transfer of hCD40L in
Combination With IFN-gamma
AUTHOR: Knippertz Ilka; Hesse Andrea; Schunder Tania; Kaempgen Eckhart;
Brenner Malcown K; Schuler Gerold; Steinkasserer Alexander; Nettelbeck
Dirk M (Reprint)
AUTHOR ADDRESS: Univ Heidelberg Hosp, German Canc Res Ctr, Helmholtz Univ
Grp Oncolyt Adenoviruses, Neuenheimer Feld 242, D-69221 Heidelberg,
Germany**Germany
AUTHOR E-MAIL ADDRESS: d.nettelbeck@dkfz-heidelberg.de
JOURNAL: Journal of Immunotherapy 32 (5): p524-538 JUN 2009 2009
ISSN: 1524-9557
DOCUMENT TYPE: Article
RECORD TYPE: Abstract

LANGUAGE: English

7/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0020918470 BIOSIS NO.: 200900258804
Vaccination Strategies for Patients with B-CLLc
AUTHOR: Okur Fatma V (Reprint); Yvon Eric; Dotti Gianpietro; Carrum George;
Heslop Helen E; Brenner Malcolm K; Fratantoni Joseph C; Peshwa Madhusudan
V; Li Linhong
AUTHOR ADDRESS: Baylor Coll Med, Ctr Cell and Gene Therapy, Houston, TX
77030 USA**USA
JOURNAL: Blood 112 (11): p733 NOV 16 2008 2008
CONFERENCE/MEETING: 50th Annual Meeting of the American-
Society-of-Hematology San Francisco, CA, USA December 06 -09, 2008;
20081206
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

7/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0020855343 BIOSIS NO.: 200900195677
CD40 ligation converts TGF-beta-secreting tolerogenic CD4(-)8(-) dendritic
cells into IL-12-secreting immunogenic ones
AUTHOR: Zhang Xueshu; Kedl Ross M; Xiang Jim (Reprint)
AUTHOR ADDRESS: Univ Saskatchewan, Saskatchewan Canc Agcy, Canc Res Unit,
20 Campus Dr, Saskatoon, SK S7N 0W0, Canada**Canada
AUTHOR E-MAIL ADDRESS: Jim.Xiang@saskcancer.ca
JOURNAL: Biochemical and Biophysical Research Communications 379 (4): p
954-958 FEB 20 2009 2009
ITEM IDENTIFIER: doi:10.1016/j.bbrc.2008.12.179
ISSN: 0006-291X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

7/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

19108867 BIOSIS NO.: 200600454262
Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in
vivo following intratumoral administration of viral vectors or transduced
dendritic cells
AUTHOR: Yurkovetsky Zoya R; Shurin Galina V; Barry Denise A; Schuh Andre C;
Shurin Michael R; Robbins Paul D (Reprint)
AUTHOR ADDRESS: Univ Pittsburgh, Sch Med, Dept Biochem and Mol Genet, W1246
Biomed Sci Tower, Pittsburgh, PA 15261 USA**USA
AUTHOR E-MAIL ADDRESS: probb@pitt.edu
JOURNAL: JOURNAL OF GENE MEDICINE 8 (2): p129-137 FEB 2006 2006
ISSN: 1099-498X_(print) 1521-2254_(electronic)
DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

7/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

18788546 BIOSIS NO.: 200600133941
Vector prime-protein boost vaccine induces immune response against
"self-antigens" associated with epithelial neoplasms and tumor vascular
endothelial cells.
AUTHOR: Tang Yucheng (Reprint); Maynard Jonathan; Akbulut Hakan; Linton
Phyllis-Jean; Deisseroth Albert B
AUTHOR ADDRESS: Sidney Kimmel Canc Ctr, Gene Therapy Program, San Diego, CA
USA**USA
JOURNAL: Blood 106 (11, Part 2): p471B-472B NOV 16 2005 2005
CONFERENCE/MEETING: 47th Annual Meeting of the
American-Society-of-Hematology Atlanta, GA, USA December 10 -13, 2005;
20051210
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

7/3/6 (Item 6 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17781412 BIOSIS NO.: 200400148073
An adenoviral vector cancer vaccine that delivers a tumor associated
antigen/CD40-ligand fusion protein to dendritic cells in vivo and thereby
breaks tolerance to tumor associated self antigens.
AUTHOR: Tang Yucheng (Reprint); Zhang Lixin (Reprint); Akbulut Hakan
(Reprint); Linton Phyllis-Jean (Reprint); Deisseroth Albert B (Reprint)
AUTHOR ADDRESS: Genetic Therapy Program, Sidney Kimmel Cancer Center, San
Diego, CA, USA**USA
JOURNAL: Blood 102 (11): p745a November 16, 2003 2003
MEDIUM: print
CONFERENCE/MEETING: 45th Annual Meeting of the American Society of
Hematology San Diego, CA, USA December 06-09, 2003; 20031206
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

7/3/7 (Item 7 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17649370 BIOSIS NO.: 200400016354
Enhanced effector and memory CTL responses generated by incorporation of
receptor activator of NF-kappaB (RANK)/RANK ligand costimulatory
molecules into dendritic cell immunogens expressing a human
tumor-specific antigen.
AUTHOR: Wiethe Carsten; Dittmar Kurt; Doan Tracy; Lindenmaier Werner;
Tindle Robert (Reprint)

AUTHOR ADDRESS: Sir Albert Sakzewski Virus Research Centre, Royal Children's Hospital, Herston Road, Herston, QLD, 4029, Australia**
Australia

AUTHOR E-MAIL ADDRESS: r.tindle@mailbox.uq.edu.au

JOURNAL: Journal of Immunology 171 (8): p4121-4130 October 15, 2003 2003

MEDIUM: print

ISSN: 0022-1767 _ (ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

7/3/8 (Item 8 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2010 The Thomson Corporation. All rts. reserv.

17530335 BIOSIS NO.: 200300487992

Injection of adenoviral vector encoding a secretable form
of the E7/CD40 ligand generates immunoresistance to E7
positive cell lines for over 1 year.

AUTHOR: Tang Yucheng (Reprint); Zhang Lixin (Reprint); Maynard Jonathan (Reprint); Deisseroth Albert (Reprint)

AUTHOR ADDRESS: Sidney Kimmel Cancer Center, San Diego, CA, USA**USA
JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 44 p589 July 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 94th Annual Meeting of the American Association for Cancer Research Washington, DC, USA July 11-14, 2003; 20030711

ISSN: 0197-016X

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

7/3/9 (Item 9 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2010 The Thomson Corporation. All rts. reserv.

17398836 BIOSIS NO.: 200300357555

Treatment of High-Risk Acute Leukemia with an Autologous Vaccine Expressing Transgenic IL-2 and CD40L.

AUTHOR: Rousseau Raphael (Reprint); Biagi Ettore (Reprint); Yvon Eric (Reprint); Mei Zhuyong (Reprint); Inman Shannon (Reprint); Rill Donna (Reprint); Heslop Helen (Reprint); Popat Uday (Reprint); Gee Adrian (Reprint); Krance Robert (Reprint); Carrum George (Reprint); Alcoser Pat (Reprint); Rodgers Sherryl (Reprint); Kuehnle Ingrid (Reprint); Margolin Judith (Reprint); Brenner Malcolm (Reprint)

AUTHOR ADDRESS: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA**USA

JOURNAL: Blood 100 (11): pAbstract No. 3420 November 16, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

7/3/10 (Item 10 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16593405 BIOSIS NO.: 200200186916
Membrane-stabilized chimeric tumor necrosis factor for gene therapy of B cell malignancies
AUTHOR: Cantwell Mark J (Reprint); Li Mei (Reprint); Prussak Charles (Reprint); Kipps Thomas J
AUTHOR ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA**USA
JOURNAL: Blood 98 (11 Part 1): p423a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

7/3/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16140629 BIOSIS NO.: 200100312468
Immune responses induced by autologous non-Hodgkin's lymphoma B cells expressing the CD40 ligand and interleukin-2 transgenes
AUTHOR: Takahashi Satoshi (Reprint); Rousseau Raphael F (Reprint); Yotnda Patricia (Reprint); Mei Zhuyong (Reprint); Smith Susan (Reprint); Donna Rill (Reprint); Brenner Malcolm K (Reprint)
AUTHOR ADDRESS: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA**USA
JOURNAL: Blood 96 (11 Part 1): p340a November 16, 2000 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

7/3/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

15485486 BIOSIS NO.: 200000203799
Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
AUTHOR: Chirmule Narendra; Raper Steven E; Burkly Linda; Thomas David; Tazelaar John; Hughes Joseph V; Wilson James M (Reprint)
AUTHOR ADDRESS: University of Pennsylvania, 3601 Spruce St., 204 Wistar Institute, Philadelphia, PA, 19104, USA**USA
JOURNAL: Journal of Virology 74 (7): p3345-3352 April, 2000 2000
MEDIUM: print
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

7/3/13 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0078161960 EMBASE/Medline No: 2000211248
CD40 ligand (CD154) enhances the Th1 and antibody responses to
respiratory syncytial virus in the BALB/c mouse
Tripp R.A.; Jones L.; Anderson L.J.; Brown M.P.
Div. of Viral and Rickettsial Dis., Natl. Center of Infectious Diseases,
Centers for Dis. Contr. and Prev., Atlanta, GA 30333, United States;
Centers for Dis. Contr. and Prev., MS G09, 1600 Clifton Road, Atlanta, GA
30333, United States
AUTHOR EMAIL: rgt3@cdc.gov
CORRESP. AUTHOR/AFFIL: Tripp R.A.: Centers for Dis. Control/Prevention,
1600 Clifton Road, Atlanta, GA 30333, United States
CORRESP. AUTHOR EMAIL: rgt3@cdc.gov

Journal of Immunology (J. Immunol.) (United States) July 3, 2000,
164/11 (5913-5921)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 71

7/3/14 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0069486677 EMBASE/Medline No: 16256021
Construction of recombinant adenovirus expressing sCD40L-Ig
Li Z.L.; Tian P.X.; Xue W.J.
Renal Disease Center of First Affiliated Hospital, Xi'an Jiaotong
University, Xi'an 710061, China.
CORRESP. AUTHOR/AFFIL: Li Z.L.: Renal Disease Center of First Affiliated
Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
CORRESP. AUTHOR EMAIL: Lizhaolun1@sina.com.cn

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and
molecular immunology (Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi) (China)
November 1, 2005, 21/6 (668-671)
ISSN: 1007-8738
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
FILE SEGMENT: Medline
LANGUAGE: Chinese

7/3/15 (Item 1 from file: 155)
DIALOG(R)File 155: MEDLINE (R)
(c) format only 2010 Dialog. All rts. reserv.

32969660 PMID: 20423644
[Construction and identification of recombinant adenovirus vector
expressing IkappaBalphalpha-IRES2-shCD40L.]
Ding Xiao-Ming; Niu Xiao-Li; Xue Wu-Jun; Li Yang
Department of Renal Transplantation, Center of Nephropathy, First
Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and
molecular immunology (China) May 2010, 26 (5) p416-9, ISSN 1007-8738
--Print 1007-8738--Linking Journal Code: 101139110

Publishing Model Print
Document type: English Abstract; Journal Article
Languages: CHINESE
Main Citation Owner: NLM
Record type: In Data Review
? t s/7/9-13

7/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17398836 BIOSIS NO.: 200300357555
Treatment of High-Risk Acute Leukemia with an Autologous Vaccine Expressing Transgenic IL-2 and CD40L.

AUTHOR: Rousseau Raphael (Reprint); Biagi Ettore (Reprint); Yvon Eric (Reprint); Mei Zhiyong (Reprint); Inman Shannon (Reprint); Rill Donna (Reprint); Heslop Helen (Reprint); Popat Uday (Reprint); Gee Adrian (Reprint); Krance Robert (Reprint); Carrum George (Reprint); Alcoser Pat (Reprint); Rodgers Sherryl (Reprint); Kuehnle Ingrid (Reprint); Margolin Judith (Reprint); Brenner Malcolm (Reprint)

AUTHOR ADDRESS: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA**USA

JOURNAL: Blood 100 (11): pAbstract No. 3420 November 16, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

ABSTRACT: Leukemic cells generally do not express the costimulatory surface molecules necessary for induction of a T-cell response. Consequently, they induce specific T-cell anergy. Engagement of CD40L augments antigen presentation by normal and malignant B cells, and by antigen-presenting cells (APC) by up-regulating the expression of adhesion, costimulatory and MHC molecules. Stimulation of APC through the CD40-CD40L pathway bypasses the helper T-cell mechanism in activating specific cytotoxic T cells. In murine models, CD40L augments the immune response against CD40-malignancies by stimulating activated CD4+ and CD8+ T cells. Hence, activation of CD40+ leukemia cells by CD40L generates an anti-tumor response in leukemia-bearing mice and the effect is potentiated by IL2 (Bilbo et al., Blood 1997;90:1927). We developed a Phase I study to assess the feasibility, safety and immunologic efficacy of an IL2- and CD40L-expressing tumor vaccine in patients with high-risk acute leukemia. The predicted relapse risk for this group was >50% at 2 years. Autologous skin fibroblasts were transduced with adenoviral

vectors encoding human IL-2 and ***CD40L***. High-risk patients in complete or partial cytological remission received up to six s.c. injections of their gene-modified ***CD40L*** and IL-2 fibroblasts, and leukemic blasts, separated by one-two weeks in the absence of concurrent therapy. Patients received a fixed dose of IL-2 secreting fibroblasts (2x1E7 per injection) and leukemic blasts (2x1E7 per injection) throughout the treatment protocol, while the dose of CD40L-secreting fibroblasts were escalated from 2x1E5 (level 1) to 2x1E7 (level 3) per injection. To date, nine patients (2 adults, 7 children) with AML (3 patients) or B-ALL (5 patients) have been studied. All but 1 patient were in complete remission on enrollment, 7 post allogeneic bone marrow transplantation and 1 post chemotherapy regimen. All patients were off immunosuppressive drugs. No severe adverse reactions were noted. Of the 8 evaluable patients, one relapsed (skull

infiltrate) after 22 weeks. All other patients remain disease free 1 to 31 months after the 1st injection (disease free survival at 12 months = 87.5%). Injection-site biopsies revealed increased cellularity due to infiltration of CD3+ cells. Systemically, we observed a significant expansion of the CD4+ (259+/-35/ml to 519+/-66/ml, a 2-fold increase, P=0.004) and the CD3+CD25+ T-cell (100+/-20/ml to 189+/-11/ml, a 1.9-fold increase, P=0.006) populations. Using the ELISPOT assay, we found an increase in IFNgamma- and IL4-spot forming cells reactive to their autologous blasts after 3 injections (IFNgamma: median 10 pre to 190 post; IL-4: median 10 pre to 40 post). Two of 8 evaluable patients produced IgG antibodies that bound to their autologous blasts. Thus, a vaccine combining transgenic skin fibroblasts secreting CD40L with IL-2 and autologous leukemic blasts can be safely administered to patients in remission of acute leukemia, and even in patients post allogeneic bone marrow transplantation, it can produce immunomodulation. A larger study with continued follow up should indicate whether such adjuvant therapy has clinical benefit.

7/7/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16593405 BIOSIS NO.: 200200186916
Membrane-stabilized chimeric tumor necrosis factor for gene therapy of B cell malignancies
AUTHOR: Cantwell Mark J (Reprint); Li Mei (Reprint); Prussak Charles (Reprint); Kipps Thomas J
AUTHOR ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA**USA
JOURNAL: Blood 98 (11 Part 1): p423a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: Tumor necrosis factor (TNF) first was identified as a molecule that could induce apoptosis (previously considered necrosis) of tumor cells when injected into tumor-bearing animals. Clinical trials in patients with various cancers, however, revealed TNF had a low therapeutic index, in part due to the high systemic toxicity of soluble TNF, thereby greatly limiting the concentration of TNF that could be achieved at sites of tumor *in vivo*. Nevertheless, encouraging clinical responses were observed, particularly in patients with B cell malignancies (Selby *et. al.*, Br J Cancer. 56:803-808, 1987). Transduction of tumor cells with genes encoding TNF might be an effective strategy for treatment of such neoplastic diseases. However, this strategy may also generate unacceptable toxicities, as the membrane-associated pro-cytokine of wild-type TNF (wtTNF) is readily cleaved, releasing a soluble cytokine that diffuses rapidly to distal sites *in vivo*. Transfer of genes encoding membrane-stabilized forms of TNF, on the other hand, may allow for high-level local expression of molecules that can effect TNF-signaling without the systemic toxicity associated with soluble TNF. To this end, we generated chimeric TNF genes encoding the receptor-binding domain of TNF spliced onto transmembrane domains of other members of the TNF family (e.g. CD70, ***CD154***, TRAIL, and Fas-Ligand). In addition, we introduced an in-frame deletion to generate a truncated TNF gene (DELTATNF) lacking the known site(s) for cleavage by matrix

metalloproteinases. Finally, we generated recombinant ***adenovirus*** (Ad) ***vectors*** encoding these recombinant TNF genes. These Ad vectors were used to transduce cells that subsequently were examined for expression of soluble and membrane-anchored molecules with TNF activity. We discovered that cells transduced with Ad encoding the chimeric CD154-TNF (Ad-CD154-TNF) expressed significantly higher levels of cell-surface TNF than did cells equally transduced with Ad-wtTNF, Ad-DELTATNF, or any one of the other chimeric constructs. Moreover, cells that expressed CD154-TNF specifically could interact with both p55 and p75 TNF-receptors (CD120a and CD120b) to effect TNF-signaling. On the other hand, cells expressing the chimeric CD154-TNF gene secreted near-negligible amounts of soluble TNF that were 1/1,000th or 1/100th of that produced by equivalent numbers of cells transduced with Ad-wtTNF or Ad-DELTATNF, respectively. Neoplastic B cells from patients with chronic lymphocytic leukemia, follicular lymphoma, or multiple myeloma also could be transduced with Ad-CD154-TNF. Transduced B cells expressed high surface levels of TNF without releasing detectable amounts of soluble TNF. Furthermore, transduction of the neoplastic B cells with Ad-CD154-TNF induced expression of immune co-stimulatory molecules that are important for antigen presentation. We conclude that CD154-TNF represents a novel type of membrane-stabilized TNF that has potent biologic activity. The use of such molecules could mitigate the risk of systemic toxicity caused by soluble TNF, potentially allowing for the application of TNF gene therapy in patients with B cell malignancies.

7/7/11 (Item 11 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16140629 BIOSIS NO.: 200100312468
Immune responses induced by autologous non-Hodgkin's lymphoma B cells expressing the CD40 ligand and interleukin-2 transgenes
AUTHOR: Takahashi Satoshi (Reprint); Rousseau Raphael F (Reprint); Yotnda Patricia (Reprint); Mei Zhuyong (Reprint); Smith Susan (Reprint); Donna Rill (Reprint); Brenner Malcolm K (Reprint)
AUTHOR ADDRESS: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA**USA
JOURNAL: Blood 96 (11 Part 1): p340a November 16, 2000 2000
MEDIUM: print
CONFERENCE/MEETING: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000; 20001201
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The malignant B cells of non-Hodgkin's lymphoma (B-NHL) express peptides derived from tumor specific antigens (such as immunoglobulin idiotypes), and also express major histocompatibility complex (MHC) antigens. However, they do not express co-stimulatory molecules which likely contributes to their protection from host antitumor immunity. To stimulate NHL-specific immune responses, we attempted to transfer the human CD40 ligand (hCD40L) gene to B-NHL cells and enhance their co-stimulatory potential. We found an ***adenoviral*** ***vector*** encoding human CD40L (AdhCD40L) was ineffective at transducing B-NHL cells, which lack adenoviral receptors, including CAR (the coxsackievirus B- ***adenovirus*** receptors) and alphav integrins. However, pre-culture of the B-NHL cells with human embryonic lung fibroblast line MRC-5 significantly upregulated expression of integrins

and markedly increased their susceptibility to adenoviral ***vector*** transduction. After pre-stimulation, transduction with AdhCD40L increased ***CD40L*** expression on B-NHL cells from $1.3 \pm 0.2\%$ to $40.8 \pm 11.9\%$ (n=7). No significant increase in ***CD40L*** expression was obtained without pre-culture or with control advectors. Expression of transgenic human CD40L was in turn associated with upregulation of other co-stimulatory molecules including B7-1/-2 (CD80 expression before transduction: $12.2 \pm 6.3\%$; after transduction: $46.0 \pm 10.4\%$; CD86 expression before transduction: $42.9 \pm 6.2\%$; after transduction: $71.3 \pm 7.9\%$). Transduced B-NHL cells were now able to stimulate autologous T cells to proliferate and secrete Th1 cytokines, but the stimulated T cells were unable to recognize unmodified lymphoma cells - a requirement for an effective tumor vaccine. Our previous studies of murine lymphoma models suggested that CD40L and interleukin-2 (IL2) in combination were more potent than either molecule alone. We therefore transduced B-NHL cells with AdhCD40L and AdhIL2 (IL2 production before transduction: below limit of detection; on day 3: $10.1 \pm 5.2\text{ng}$ of IL2/106 cells/24 hours). Although IL2 transduction alone had little effect, admixture of hCD40L- and hIL2-gene transduced cells enhanced initial T-cell activation and also generated autologous T cells capable of specifically recognizing and killing parental B-NHL cells via MHC restricted cytotoxic T lymphocytes. These findings suggest that the combination of CD40L and IL2 gene-modified B-NHL cells may be capable of inducing a cytotoxic immune response *in vivo*.

7/7/12 (Item 12 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

15485486 BIOSIS NO.: 200000203799
Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
AUTHOR: Chirmule Narendra; Raper Steven E; Burkly Linda; Thomas David; Tazelaar John; Hughes Joseph V; Wilson James M (Reprint)
AUTHOR ADDRESS: University of Pennsylvania, 3601 Spruce St., 204 Wistar Institute, Philadelphia, PA, 19104, USA*^{USA}
JOURNAL: Journal of Virology 74 (7): p3345-3352 April, 2000 2000
MEDIUM: print
ISSN: 0022-538X
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The interaction between CD40 on B cells and CD40 ligand (CD40L) on activated T cells is important for B-cell differentiation in T-cell-dependent humoral responses. We have extended our previous murine studies of CD40-CD40L in adenoviral ***vector***-mediated immune responses to rhesus monkeys. Primary immune responses to adenoviral vectors and the ability to readminister vector were studied in rhesus monkeys in the presence or absence of a transient treatment with a humanized anti-CD40 ***ligand*** antibody (hu5C8). Adult animals were treated with hu5C8 at the time ***vector*** was instilled into the lung. Immunological analyses demonstrated suppression of adenovirus-induced lymphoproliferation and cytokine responses (interleukin-2 (IL-2), gamma interferon, IL-4, and IL-10) in hu5C8-treated animals. Animals treated with hu5C8 secreted adenovirus-specific immunoglobulin M (IgM) levels comparable to control animals, but did not secrete IgA or develop neutralizing antibodies; consequently, the animals could be readministered with adenovirus vector expressing alkaline

phosphatase. A second study was designed to examine the long-term effects on immune functions of a short course of hu5C8. Acute hu5C8 treatment resulted in significant and prolonged inhibition of the adenovirus-specific humoral response well beyond the time hu5C8 effects were no longer significant. These studies demonstrate the potential of hu5C8 as an immunomodulatory regimen to enable administration of adenoviral vectors, and they advocate testing this model in humans.

7/7/13 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0078161960 EMBASE/Medline No: 2000211248
CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse
Tripp R.A.; Jones L.; Anderson L.J.; Brown M.P.
Div. of Viral and Rickettsial Dis., Natl. Center of Infectious Diseases, Centers for Dis. Contr. and Prev., Atlanta, GA 30333, United States; Centers for Dis. Contr. and Prev., MS G09, 1600 Clifton Road, Atlanta, GA 30333, United States
AUTHOR EMAIL: rgt3@cdc.gov
CORRESP. AUTHOR/AFFIL: Tripp R.A.: Centers for Dis. Control/Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States
CORRESP. AUTHOR EMAIL: rgt3@cdc.gov

Journal of Immunology (J. Immunol.) (United States) July 3, 2000, 164/11 (5913-5921)
CODEN: JOIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 71

CD40 ligand (CD40L) is a cell surface costimulatory molecule expressed mainly by activated T cells. CD40L is critically important for T-B cell and T cell-dendritic cell interactions. CD40L expression promotes Th1 cytokine responses to protein Ags and is responsible for Ig isotype switching in B cells. Respiratory syncytial virus (RSV) is an important pathogen of young children and the elderly, which causes bronchiolitis and pneumonia. Studies of mice infected with RSV suggest that a Th2 cytokine response may be responsible for enhanced pulmonary disease. To investigate the effect CD40L has on RSV immunity, mice were infected simultaneously with RSV and either an empty control adenovirus vector or one expressing CD40L or were coimmunized with plasmid DNA vectors expressing CD40L and RSV F and/or G proteins and subsequently challenged with RSV. The kinetics of the intracellular and ***secreted*** cytokine responses, the cytotoxic T lymphocyte precursor frequency, NO levels in lung lavage, rates of virus clearance, and anti-RSV Ab titers were determined. These studies show that coincident expression of CD40L enhances the Th1 (IL-2 and IFN-gamma) cytokine responses, increases the expression of TNF-alpha and NO, accelerates virus clearance, and increases the anti-F and anti-G Ab responses. These data suggest that CD40L may have the adjuvant properties needed to optimize the safety and efficacy of RSV vaccines.

? ds

Set	Items	Description
S1	166	E1-E4
S2	269	AU='ZHANG LIXIN'
S3	12	(S1 OR S2) AND ((ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?) AND (CD40L OR CD154 OR CD40(W)LIGAND))

S4 10 RD S3 (unique items)
S5 379 (ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?) (20N) (CD40L OR CD1-
54 OR CD40 (W)LIGAND)
S6 29 (ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?) (20N) (CD40L OR CD1-
54 OR CD40 (W)LIGAND) (20N) (SECRET?)
S7 15 RD S6 (unique items)
? s (adenoviral or adenovirus) (20n) (vector?) (20n) (Cd40L or cd154 or cd40(w)ligand)
and (cd40L or cd40(w)ligand or cd154) (20n) (secret?)
42047 ADENOVIRAL
136081 ADENOVIRUS
694836 VECTOR?
10347 CD40L
4611 CD154
42860 CD40
661511 LIGAND
19956 CD40 (W)LIGAND
384 (ADENOVIRAL OR ADENOVIRUS) (20N) VECTOR? (20N) ((CD40L OR
CD154) OR CD40 (W)LIGAND)
10347 CD40L
42860 CD40
661511 LIGAND
19956 CD40 (W)LIGAND
4611 CD154
1567357 SECRET?
1381 ((CD40L OR CD40 (W)LIGAND) OR CD154) (20N) SECRET?
S8 28 (ADENOVIRAL OR ADENOVIRUS) (20N) (VECTOR?) (20N) (CD40L OR
CD154 OR CD40 (W)LIGAND) AND (CD40L OR CD40 (W)LIGAND OR
CD154) (20N) (SECRET?)
? rd s8
S9 19 RD S8 (unique items)
? t s9/3/all

9/3/1 (Item 1 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0021031254 BIOSIS NO.: 200900372691
Generation of Human Dendritic Cells That Simultaneously Secrete IL-12 and
Have Migratory Capacity by Adenoviral Gene Transfer of hCD40L in
Combination With IFN-gamma
AUTHOR: Knippertz Ilka; Hesse Andrea; Schunder Tania; Kaempgen Eckhart;
Brenner Malcbyn K; Schuler Gerold; Steinkasserer Alexander; Nettelbeck
Dirk M (Reprint)
AUTHOR ADDRESS: Univ Heidelberg Hosp, German Canc Res Ctr, Helmholtz Univ
Grp Oncol Adenoviruses, Neuenheimer Feld 242, D-69221 Heidelberg,
Germany**Germany
AUTHOR E-MAIL ADDRESS: d.nettelbeck@dkfz-heidelberg.de
JOURNAL: Journal of Immunotherapy 32 (5): p524-538 JUN 2009 2009
ISSN: 1524-9557
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/2 (Item 2 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

0020918470 BIOSIS NO.: 200900258804
Vaccination Strategies for Patients with B-CLLc
AUTHOR: Okur Fatma V (Reprint); Yvon Eric; Dotti Gianpietro; Carrum George;

Heslop Helen E; Brenner Malcolm K; Fratantoni Joseph C; Peshwa Madhusudan V; Li Linhong
AUTHOR ADDRESS: Baylor Coll Med, Ctr Cell and Gene Therapy, Houston, TX 77030 USA**USA
JOURNAL: Blood 112 (11): p733 NOV 16 2008 2008
CONFERENCE/MEETING: 50th Annual Meeting of the American-Society-of-Hematology San Francisco, CA, USA December 06 -09, 2008; 20081206
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

9/3/3 (Item 3 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

19108867 BIOSIS NO.: 200600454262
Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells
AUTHOR: Yurkovetsky Zoya R; Shurin Galina V; Barry Denise A; Schuh Andre C; Shurin Michael R; Robbins Paul D (Reprint)
AUTHOR ADDRESS: Univ Pittsburgh, Sch Med, Dept Biochem and Mol Genet, W1246 Biomed Sci Tower, Pittsburgh, PA 15261 USA**USA
AUTHOR E-MAIL ADDRESS: probb@pitt.edu
JOURNAL: JOURNAL OF GENE MEDICINE 8 (2): p129-137 FEB 2006 2006
ISSN: 1099-498X_(print) 1521-2254_(electronic)
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

9/3/4 (Item 4 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

18573019 BIOSIS NO.: 200510267519
Soluble factors secreted from CD40 ligand-transfected dendritic cells enhance TRAIL-induced apoptosis of multiple myeloma.
AUTHOR: Tomibara Kei (Reprint); Kato Kazunori; Hamada Hiroyumi
AUTHOR ADDRESS: Sapporo Med Univ, Dept Mol Med, Sapporo, Hokkaido, Japan** Japan
JOURNAL: Blood 104 (11, Part 2): p300B NOV 16 2004 2004
CONFERENCE/MEETING: 46th Annual Meeting of the American-Society-of-Hematology San Diego, CA, USA December 04 -07, 2004; 20041204
SPONSOR: Amer Soc Hematol
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract
RECORD TYPE: Abstract
LANGUAGE: English

9/3/5 (Item 5 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17781412 BIOSIS NO.: 200400148073

An adenoviral vector cancer vaccine that delivers a tumor associated antigen/CD40-ligand fusion protein to dendritic cells in vivo and thereby breaks tolerance to tumor associated self antigens.

AUTHOR: Tang Yucheng (Reprint); Zhang Lixin (Reprint); Akbulut Hakan (Reprint); Litton Phyllis-Jean (Reprint); Deisseroth Albert B (Reprint)

AUTHOR ADDRESS: Genetic Therapy Program, Sidney Kimmel Cancer Center, San Diego, CA, USA**USA

JOURNAL: Blood 102 (11): p745a November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

9/3/6 (Item 6 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2010 The Thomson Corporation. All rts. reserv.

17649370 BIOSIS NO.: 200400016354

Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF- κ B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen.

AUTHOR: Wietho Carsten; Dittmar Kurt; Doan Tracy; Lindenmaier Werner; Tindle Robert (Reprint)

AUTHOR ADDRESS: Sir Albert Sakzewski Virus Research Centre, Royal Children's Hospital, Herston Road, Herston, QLD, 4029, Australia** Australia

AUTHOR E-MAIL ADDRESS: r.tindle@mailbox.uq.edu.au

JOURNAL: Journal of Immunology 171 (8): p4121-4130 October 15, 2003 2003

MEDIUM: print

ISSN: 0022-1767 _(ISSN print)

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

9/3/7 (Item 7 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2010 The Thomson Corporation. All rts. reserv.

17530335 BIOSIS NO.: 200300487992

Injection of adenoviral vector encoding a secretable form of the E7/CD40 ligand generates immunoresistance to E7 positive cell lines for over 1 year.

AUTHOR: Tang Yucheng (Reprint); Zhang Lixin (Reprint); Maynard Jonathan (Reprint); Deisseroth Albert (Reprint)

AUTHOR ADDRESS: Sidney Kimmel Cancer Center, San Diego, CA, USA**USA

JOURNAL: Proceedings of the American Association for Cancer Research Annual Meeting 44 p589 July 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 94th Annual Meeting of the American Association for Cancer Research Washington, DC, USA July 11-14, 2003; 20030711

ISSN: 0197-016X

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

9/3/8 (Item 8 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

17398836 BIOSIS NO.: 200300357555
Treatment of High-Risk Acute Leukemia with an Autologous Vaccine Expressing Transgenic IL-2 and CD40L.

AUTHOR: Rousseau Raphael (Reprint); Biagi Ettore (Reprint); Yvon Eric (Reprint); Mei Zhu Yong (Reprint); Inman Shannon (Reprint); Rill Donna (Reprint); Heslop Helen (Reprint); Popat Uday (Reprint); Gee Adrian (Reprint); Krance Robert (Reprint); Carrum George (Reprint); Alcoser Pat (Reprint); Rodgers Sherryl (Reprint); Kuehnle Ingrid (Reprint); Margolin Judith (Reprint); Brenner Malcolm (Reprint)

AUTHOR ADDRESS: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA**USA

JOURNAL: Blood 100 (11): pAbstract No. 3420 November 16, 2002 2002

MEDIUM: print

CONFERENCE/MEETING: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002; 20021206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

9/3/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16626659 BIOSIS NO.: 200200220170
Comparing the efficiency of adenoviral gene transfer of CD40-ligand (CD154) versus treatment with immunostimulatory DNA-sequences as cellular anti-lymphoma vaccines in the murine A20 model

AUTHOR: Rieger Roman (Reprint); Kipps Thomas J (Reprint)

AUTHOR ADDRESS: School of Medicine, Division of Hematology/Oncology, University of California, La Jolla, CA, USA**USA

JOURNAL: Blood 98 (11 Part 1): p609a November 16, 2001 2001

MEDIUM: print

CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster

RECORD TYPE: Abstract

LANGUAGE: English

9/3/10 (Item 10 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16593405 BIOSIS NO.: 200200186916
Membrane-stabilized chimeric tumor necrosis factor for gene therapy of B cell malignancies

AUTHOR: Cantwell Mark J (Reprint); Li Mei (Reprint); Prussak Charles (Reprint); Kipps Thomas J

AUTHOR ADDRESS: Tragen Pharmaceuticals, La Jolla, CA, USA**USA

JOURNAL: Blood 98 (11 Part 1): p423a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

9/3/11 (Item 1 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0080486566 EMBASE/Medline No: 2005130724
Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes
Biagi E.; Dotti G.; Yvon E.; Lee E.; Pule M.; Vigouroux S.; Gottschalk S.; Popat U.; Rousseau R.; Brenner M.
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hosp./Texas Children's H., Houston, TX, United States; Center for Cell and Gene Therapy, 1102 Bates St., Houston, TX 77030, United States
AUTHOR EMAIL: exbiagi@txccc.org
CORRESP. AUTHOR/AFFIL: Biagi E.: Center for Cell and Gene Therapy, 1102 Bates St., Houston, TX 77030, United States
CORRESP. AUTHOR EMAIL: exbiagi@txccc.org

Blood (Blood) (United States) March 15, 2005, 105/6 (2436-2442)
CODEN: BLOOA ISSN: 0006-4971
DOI: 10.1182/blood-2004-07-2556
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 38

9/3/12 (Item 2 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0078161960 EMBASE/Medline No: 2000211248
CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse
Tripp R.A.; Jones L.; Anderson L.J.; Brown M.P.
Div. of Viral and Rickettsial Dis., Natl. Center of Infectious Diseases, Centers for Dis. Contr. and Prev., Atlanta, GA 30333, United States; Centers for Dis. Contr. and Prev., MS G09, 1600 Clifton Road, Atlanta, GA 30333, United States
AUTHOR EMAIL: rgt3@cdc.gov
CORRESP. AUTHOR/AFFIL: Tripp R.A.: Centers for Dis. Control/Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States
CORRESP. AUTHOR EMAIL: rgt3@cdc.gov

Journal of Immunology (J. Immunol.) (United States) July 3, 2000, 164/11 (5913-5921)
CODEN: JCIIMA ISSN: 0022-1767
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
LANGUAGE: English SUMMARY LANGUAGE: English
NUMBER OF REFERENCES: 71

9/3/13 (Item 3 from file: 73)
DIALOG(R)File 73:EMBASE
(c) 2010 Elsevier B.V. All rts. reserv.

0069486677 EMBASE/Medline No: 16256021
Construction of recombinant adenovirus expressing sCD40L-Ig
Li Z.L.; Tian P.X.; Xue W.J.
Renal Disease Center of First Affiliated Hospital, Xi'an Jiaotong
University, Xi'an 710061, China.
CORRESP. AUTHOR/AFFIL: Li Z.L.: Renal Disease Center of First Affiliated
Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
CORRESP. AUTHOR EMAIL: Lizhaolun@sina.com.cn

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and
molecular immunology (Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi) (China)
November 1, 2005, 21/6 (668-671)
ISSN: 1007-8738
DOCUMENT TYPE: Journal; Article RECORD TYPE: Abstract
FILE SEGMENT: Medline
LANGUAGE: Chinese

9/3/14 (Item 1 from file: 155)
DIALOG(R)File 155:MEDLINE(R)
(c) format only 2010 Dialog. All rts. reserv.

32969660 PMID: 20423644
[Construction and identification of recombinant adenovirus vector
expressing IkappaBalphalpha-IRES2-shCD40L.]
Ding Xiao-Ming; Niu Xiao-Li; Xue Wu-Jun; Li Yang
Department of Renal Transplantation, Center of Nephropathy, First
Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and
molecular immunology (China) May 2010, 26 (5) p416-9, ISSN 1007-8738
--Print 1007-8738--Linking Journal Code: 101139110
Publishing Model Print
Document type: English Abstract; Journal Article
Languages: CHINESE
Main Citation Owner: NLM
Record type: In Data Review

9/3/15 (Item 1 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2010 American Chemical Society. All rts. reserv.

147008378 CA: 147(1)8378d PATENT
Fusion proteins comprising CD40 ligand and pathogen or tumor antigen as
vaccines against infection or cancer
INVENTOR(AUTHOR): Tang, Yucheng; Deisseroth, Albert
LOCATION: USA
ASSIGNEE: Sidney Kimmel Cancer Center
PATENT: PCT International ; WO 200756266 A2 DATE: 20070518
APPLICATION: WO 2006US43164 (20061106) *US 2005PV734136 (20051107) *US
2006PV755885 (20060104) *US 2006PV789270 (20060404) *US 2006PV793206
(20060419) *US 2006PV853184 (20061020)
PAGES: 122pp. CODEN: PIXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
IPC/R/8 + Level Value Position Status Version Action Source Office:
A61K-0039/145 A I F B 20060101 H US
A61K-0048/00 A I L B 20060101 H US

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; GT; HN; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LA; LC; LK; LR; LS; LT; LU; LV; LY; MA; MD; MG; MK; MN; MW; MX; MY; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RS; RU; SC; SD; SE; SG; SK; SL; SM; SV; SY; TJ; TM; TN; TR; TT; TZ; UA; UG DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GO; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

9/3/16 (Item 2 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2010 American Chemical Society. All rts. reserv.

146054910 CA: 146(4)54910y JOURNAL

Chemotherapeutic agents enhance AAV2-mediated gene transfer into breast cancer cells promoting CD40 ligand-based immunotherapy

AUTHOR(S): Koppold, Bernd; Sauer, Georg; Buening, Hildegard; Hallek, Michael; Kreienberg, Rolf; Deissler, Helmut; Kurzeder, Christian

LOCATION: Department of Obstetrics and Gynecology, University of Ulm Medical School, Ulm, Germany, 89075

JOURNAL: J. Cancer Res. Clin. Oncol. (Journal of Cancer Research and Clinical Oncology) DATE: 2006 VOLUME: 132 NUMBER: 12 PAGES: 787-794

CODEN: JCROD7 ISSN: 0171-5216 LANGUAGE: English PUBLISHER: Springer

9/3/17 (Item 3 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2010 American Chemical Society. All rts. reserv.

146044177 CA: 146(3)44177a PATENT

Methods for immunotherapy of cancer using an expression vector encoding a tumor vasculature antigen (TVECA)-CD40L fusion and/or a tumor antigen vaccine

INVENTOR(AUTHOR): Tang, Yucheng; Deisseroth, Albert

LOCATION: USA

ASSIGNEE: Sidney Kimmel Cancer Center

PATENT: PCT International ; WO 2006130525 A2 DATE: 20061207

APPLICATION: WO 2006020652 (20060526) *US 2005PV686534 (20050531) *US 2006PV795686 (20060428)

PAGES: 80pp. CODEN: PIXXD2 LANGUAGE: English

PATENT CLASSIFICATIONS:

CLASS: A61K-000/A

DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY; BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD; GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KM; KN; KP; KR; KZ; LC; LK; LR; LS; LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NG; NI; NO; NZ; OM; PG; PH; PL; PT; RO; RU; SC; SD; SE; SG; SK; SL; SM; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US; UZ; VC; VN; YU; ZA DESIGNATED REGIONAL: AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU; LV; MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GO; GW; ML; MR; NE; SN; TD; TG; BW; GH; GM; KE; LS; MW; MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM

9/3/18 (Item 4 from file: 399)

DIALOG(R)File 399:CA SEARCH(R)

(c) 2010 American Chemical Society. All rts. reserv.

143095805 CA: 143(6)95805z PATENT
Vectors encoding antigen-CD40 ligand fusion proteins for generating
immunity against cancerous and infectious diseases
INVENTOR(AUTHOR): Diesseroth, Albert; Tang, Yucheng; Zhang, Wei-Wei;
Fang, Xiang-Ming
LOCATION: USA
ASSIGNEE: Sidney Kimmel Cancer Center
PATENT: PCT International ; WO 200558950 A2 DATE: 20050630
APPLICATION: WO 2004US41690 (20041210) *US 2003PV592016 (20031211)
PAGES: 65 pp. CODEN: PIXXD2 LANGUAGE: English
PATENT CLASSIFICATIONS:
CLASS: C07K-014/47A
DESIGNATED COUNTRIES: AE; AG; AL; AM; AT; AU; AZ; BA; BB; BG; BR; BW; BY;
BZ; CA; CH; CN; CO; CR; CU; CZ; DE; DK; DM; DZ; EC; EE; EG; ES; FI; GB; GD;
GE; GH; GM; HR; HU; ID; IL; IN; IS; JP; KE; KG; KP; KR; KZ; LC; LK; LR; LS;
LT; LU; LV; MA; MD; MG; MK; MN; MW; MX; MZ; NA; NI; NO; NZ; OM; PG; PH; PL;
PT; RO; RU; SC; SD; SE; SG; SK; SL; SY; TJ; TM; TN; TR; TT; TZ; UA; UG; US;
UZ; VC; VN; YU; ZA; ZM; ZW DESIGNATED REGIONAL: BW; GH; GM; KE; LS; MW;
MZ; NA; SD; SL; SZ; TZ; UG; ZM; ZW; AM; AZ; BY; KG; KZ; MD; RU; TJ; TM; AT;
BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HU; IE; IS; IT; LT; LU;
MC; NL; PL; PT; RO; SE; SI; SK; TR; BF; BJ; CF; CG; CI; CM; GA; GN; GQ; GW;
ML; MR; NE; SN; TD; TG

9/3/19 (Item 5 from file: 399)
DIALOG(R)File 399:CA SEARCH(R)
(c) 2010 American Chemical Society. All rts. reserv.

132320690 CA: 132(24)320690c JOURNAL
Readministration of adenovirus vector in nonhuman primate lungs by
blockade of CD40-CD40 ligand interactions
AUTHOR(S): Chirmule, Narendra; Raper, Steven E.; Burkly, Linda; Thomas,
David; Tazelaar, John; Hughes, Joseph V.; Wilson, James M.
LOCATION: Institute for Human Gene Therapy, Department of Molecular and
Cellular Engineering, University of Pennsylvania, Philadelphia, PA, USA
JOURNAL: J. Virol. DATE: 2000 VOLUME: 74 NUMBER: 7 PAGES: 3345-3352
CODEN: JOVIAM ISSN: 0022-538X LANGUAGE: English PUBLISHER: American
Society for Microbiology
? t s9/7/9

9/7/9 (Item 9 from file: 5)
DIALOG(R)File 5:Biosis Previews(R)
(c) 2010 The Thomson Corporation. All rts. reserv.

16626659 BIOSIS NO.: 200200220170
Comparing the efficiency of adenoviral gene transfer of CD40-ligand (CD154)
versus treatment with immunostimulatory DNA-sequences as cellular
anti-lymphoma vaccines in the murine A20 model
AUTHOR: Rieger Roman (Reprint); Kamps Thomas J (Reprint)
AUTHOR ADDRESS: School of Medicine, Division of Hematology/Oncology,
University of California, La Jolla, CA, USA*USA
JOURNAL: Blood 98 (11 Part 1): p609a November 16, 2001 2001
MEDIUM: print
CONFERENCE/MEETING: 43rd Annual Meeting of the American Society of
Hematology, Part 1 Orlando, Florida, USA December 07-11, 2001; 20011207
SPONSOR: American Society of Hematology
ISSN: 0006-4971
DOCUMENT TYPE: Meeting; Meeting Abstract; Meeting Poster
RECORD TYPE: Abstract
LANGUAGE: English

ABSTRACT: The interaction between CD40 on antigen-presenting cells like B cells and its ligand CD40L (CD154) on activated T cells plays a critical role in the initiation of immune responses, including anti-tumor immunity. This interaction induces B cells to express co-stimulatory molecules, such as CD80 (B7-1), which are necessary for efficient antigen presentation. Most B cell leukemias and lymphomas also express CD40 and are induced to express co-stimulatory molecules upon exposure to CD154-bearing cells. A20 is a BALB/c-derived B cell lymphoma line that has many features in common with human B cell neoplasms. A20 cells express B cell differentiation antigens, CD40, and high-levels of class I and class II major histocompatibility complex (MHC) antigens. Despite expression of MHC antigens required for T cell antigen presentation, A20 cells are poor antigen presenting cells (APC) and cannot stimulate significant autologous, or even allogeneic, mixed lymphocyte reactions (MLR). *****Adenovirus*** (Ad)- ***vector***** Gene transfer of murine CD40-ligand (CD154) into A20 cells results in high-level expression of CD154, which ligates CD40 on both infected and non-infected bystander A20 cells. This induces A20 cells to express immune co-stimulatory molecules, such as CD80 (B7-1), that are essential for effective APC activity. Immunostimulatory DNA sequences (ISS) containing non-methylated CpG dinucleotides within a defined motif also can induce such changes in A20 cells. We examined the antigen-presenting activity of A20 cells that were infected with Ad-CD154 versus A20 cells that were treated with the optimal concentration of ISS-ODN. A20 cells could stimulate syngeneic splenocytes to secrete IFN-gamma and to proliferate in an autologous MLR when they were incubated with ISS-ODN, but not with a control ODN. Furthermore, A20 cells also could function as effective stimulator cells in the autologous MLR when transduced with Ad-CD154, but not with an Ad vector encoding an irrelevant transgene. However, Ad-CD154-infected A20 cells were significantly more effective APC than oligonucleotide-treated cells, inducing greater T cell proliferation and 10-fold higher-level production of IFN-gamma than equivalent numbers of A20 cells that had been treated with ISS-ODN. Also, splenocytes from BALB/c mice vaccinated with Ad-CD154-infected A20 cells secreted higher amounts of IFN-gamma compared to mice vaccinated with ISS-ODN-treated A20 cells, as determined by ELISA and ELISPOT assays. In this context, Ad-CD154-infected A20 cells, but not ISS-ODN-treated A20 cells or A20 cells infected with a control Ad vector, could induce protective immunity against a lethal challenge with A20 cells in BALB/c in adoptive transfer experiments. We conclude that transduction of A20 cells with Ad-CD154 is more effective in inducing protective anti-lymphoma immunity than treatment of A20 cells with ISS-ODN.

?